Can-Fite has a mission to provide novel, effective
and safe therapeutics for major clinical needs. Can-Fite develops
small molecule drugs for treating autoimmune inflammatory conditions,
cancer and liver diseases.
Technology
Can-Fite's drug development efforts are built
on a proprietary A3 adenosine receptor platform & drug discovery
engine protected by strong multi-layered intellectual property
Pipeline
Can-Fite has a pipeline of novel highly selective,
small molecules, A3 adenosine receptor agonists, with potent activities
in autoimmune inflammatory conditions, cancer and liver diseases.
Lead
drug
Can-Fite's lead drug – CF101 – is
an oral drug with a very favorable human safety profile. CF101 is
currently in Phase IIb clinical studies for the treatment of rheumatoid
arthritis with demonstrated human proof-of-concept. Additional 2
Phase IIa studies in Psoriasis and Dry Eye Syndrome are currently
on going.
